Emerson Electric Price Target Bumped Up By Analysts Post Q3 Results

RBC Capital analyst Deane Dray raised the price target for Emerson Electric Co. (NYSE:EMR) to $102 (an upside of 17%) from $96 while…
  • RBC Capital analyst Deane Dray raised the price target for Emerson Electric Co. (NYSE:EMR) to $102 (an upside of 17%) from $96 while maintaining the Outperform rating on the shares.
  • The analyst mentions that he braced for much noise in Outperform-rated Emerson’s 3Q22 results given the portfolio moves of AspenTech closing on May 16, Therm-O-Disc divested on May 30, and pending InSinkErator divestment.
  • Dray noted that adding to the commotion were the headwinds in China and ongoing chip shortages, together nicking $180 million in revenues, mainly in Automation.
  • Dray expects to see more portfolio optimization moves at the November-29 NYC analyst meeting, if not sooner.
  • Related: Emerson Electric Reports Q3 Sales Growth Of 7%, Raises FY22 EPS Guidance
  • Mizuho Securities analyst Brett Linzey raised the price target on Emerson to $86 (a downside of 1.3%) from $85 while maintaining the Neutral rating on the shares. The analyst states that Q3 was in-line at the segment level.
  • Citi analyst Andrew Kaplowitz raised the price target on Emerson to $99 from $96 while maintaining the Buy rating on the shares.
  • The analyst states that despite some short-term sales impact brought on by supply chain issues and lockdowns in China, he still sees Emerson’s “still robust” demand trends in underlying orders as an indication that a strong demand cycle is still in motion.
  • Price Action: EMR shares are trading higher by 0.81% at $87.29 on the last check Wednesday.
Total
0
Shares
Related Posts
Read More

Achieve Life Sciences Announces Publication Of Cytisinicline Vaping Cessation Trial Results In JAMA Internal Medicine; Phase 2 ORCA-V1 Trial Showed Treatment With Cytisinicline More Than Doubled Odds Of Quitting E-Cigarettes Compared With Placebo

Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo   Cytisinicline treatment well tolerated with no serious adverse events

ACHV